Formic Acid

Formic Acid

SCHEMBL2454358

CCCCCCCOCCCCCCNC(=O)N[C@H](CC(=O)O)C[N+](C)(C)C.O=CO

nearest known ligand 0.62

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CPT2 P23786 3/20 0.62
▸ CPT1A P50416 3/20 0.62
▸ CPT1B Q92523 3/20 0.62
▸ EPHX2 P34913 3/20 0.46
▸ EPHX1 P07099 1/20 0.43
▸ MAPT P10636 2/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ MEN1 O00255 1/20 0.39
▸ GMNN O75496 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ HSP90AA1 P07900 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ BLM P54132 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ NR1H4 Q96RI1 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12304896 0.95 CPT2 (0.67) CPT2CPT1ACPT1BEPHX2EPHX1
Formic Acid SCHEMBL2454360 0.94 CPT2 (0.64) CPT2CPT1ACPT1BEPHX2EPHX1
Formic Acid SCHEMBL2454365 0.90 CPT2 (0.78) CPT2CPT1ACPT1B
SCHEMBL12304895 0.88 CPT2 (0.78) CPT2CPT1ACPT1BEPHX1SMN1; SMN2
Teglicar SCHEMBL13568151 0.88 CPT2 (0.78) CPT2CPT1ACPT1BEPHX1SMN1; SMN2
Formic Acid SCHEMBL2456295 0.87 CPT2 (0.53) CPT2CPT1ACPT1BEPHX2EPHX1
SCHEMBL12304909 0.86 CPT2 (0.67) CPT2CPT1ACPT1BEPHX2EPHX1
SCHEMBL1580325 0.86 CPT2 (0.61) CPT2CPT1ACPT1BEPHX2EPHX1
SCHEMBL1579627 0.85 CPT2 (0.86) CPT2CPT1ACPT1B
SCHEMBL2453804 0.85 CPT2 (0.86) CPT2CPT1ACPT1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110230555-A1 Enzyme Inhibitors and the Use Thereof DARA BIOSCIENCES, INC. 2011-09-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230555-A1 Enzyme Inhibitors and the Use Thereof GAA, CYP17A1, HSD17B11 CPT2 1556/4885CPT1A 466/4885CPT1B 842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback